|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||44.40 - 44.72|
|52 Week Range||38.45 - 50.65|
|PE Ratio (TTM)||10.66|
|Forward Dividend & Yield||1.64 (3.68%)|
|1y Target Est||N/A|
For 3Q17, revenues from established prescription products fell 6.5% YoY (year-over-year) at constant exchange rates to 2.26 billion euros.
Sanofi’s diabetes and cardiovascular franchises include the blockbuster diabetes drug Lantus, which contributes ~70% of all revenues for diabetes products.
Sanofi's Sanofi Genzyme franchise includes specialty care product revenues and reported revenue growth of 12.5% to 1.63 billion euros.
Sanofi (SNY) reported a growth of 4.7% in revenues at constant exchange rates to 9.05 billion euros, compared with 9.03 billion euros in 3Q16.
Sanofi’s 3Q17 earnings were released on November 2, 2017. It reported revenues of 9.05 billion euros for 3Q17, an operational growth of 4.7% YoY.
Alnylam's (ALNY) RNAi candidate, patisiran, has been granted accelerated assessment by the European Medicines Agency. The company expects to file new drug application by end of 2017.
Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.
Key highlights this week include AstraZeneca's (AZN) Q3 results and the FDA approval of the first new CMV medicine in 15 years.
Sanofi will develop and sell an oral treatment candidate for multiple sclerosis owned by U.S firm Principia Biopharma in a licensing agreement that could total $765 million, the French drugmaker said on Thursday. Under the terms of the deal, Principia will grant Sanofi an exclusive, worldwide license to develop and commercialise PRN2246, a drug currently in phase 1 clinical trial. "Sanofi will pay Principia a $40 million upfront payment, future milestone payments that could total $765 million and royalties on product sales," the companies said in a statement.
Takeda Pharmaceutical's experimental dengue vaccine has produced promising long-term results in clinical tests, boosting the Japanese company's global hopes for a product that will take on Sanofi's Dengvaxia. Japan's top drugmaker has become more international under its French CEO Christophe Weber, who took over in 2015. Sanofi's Dengvaxia is the first-ever approved vaccine for dengue, but it is not perfect and did not protect equally against the four different types of the virus in clinical tests.
Ahead of Regeneron Pharmaceuticals Inc (NASDAQ: REGN )'s quarterly report, scheduled for Wednesday, Nov. 8, the company's shares won an upgrade. Regeneron shares fell beneath Baird's price target after ...
The concept of support is not one of the first things you need to understand as an investor, but you will find it a powerful tool once you learn to use it.
Regeneron (REGN) is trading higher Friday, thanks to an upgrade from Robert W. Baird. Analysts Brian Skorney and Neena Bitritto-Garg boosted their rating on the stock from Sell to Neutral, with a $408 price target. In addition, Skorney writes that he is encouraged by the sales that Sanofi (SNY) reported for its eczema treatment Dupixent yesterday, which it sells in partnership with Regeneron.
Sanofi's (SNY) Q3 results were mixed as it reported in-line earnings and missed sales expectations. Meanwhile, the outlook for the Diabetes franchise remains weak.
The French drugmaker's under pressure diabetes treatments slid less than expected but sales of its growing multiple sclerosis products underwhelmed.
On a per-share basis, the Paris-based company said it had net income of 73 cents. Earnings, adjusted for non-recurring costs, came to $1 per share. The results met Wall Street expectations. The average ...